Page last updated: 2024-09-03

ym 529 and Cancer of Skin

ym 529 has been researched along with Cancer of Skin in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abe, R; Bucala, R; Imaizumi, T; Inagaki, Y; Inokuma, D; Nakamura, H; Nakamura, K; Shimizu, H; Shimizu, T; Sugawara, H; Takeuchi, M; Yamagishi, S; Yoshimura, A	1

Other Studies

1 other study(ies) available for ym 529 and Cancer of Skin

Article	Year
Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. The American journal of pathology, 2004, Volume: 165, Issue:6 Topics: Animals; Apoptosis; Cell Adhesion; Diphosphonates; DNA; Endothelium, Vascular; Female; Humans; Imidazoles; Melanoma, Experimental; Mice; Mice, Nude; NADPH Oxidases; Neovascularization, Pathologic; rac1 GTP-Binding Protein; Reactive Oxygen Species; Signal Transduction; Skin Neoplasms; Survival Rate; Vascular Endothelial Growth Factor A	2004

Article

Year

Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.

The American journal of pathology, 2004, Volume: 165, Issue:6

Topics: Animals; Apoptosis; Cell Adhesion; Diphosphonates; DNA; Endothelium, Vascular; Female; Humans; Imidazoles; Melanoma, Experimental; Mice; Mice, Nude; NADPH Oxidases; Neovascularization, Pathologic; rac1 GTP-Binding Protein; Reactive Oxygen Species; Signal Transduction; Skin Neoplasms; Survival Rate; Vascular Endothelial Growth Factor A

2004